Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
Recruiting · Phase 3 · NCT06003387
Conditions: Hemophilia B
At a glance
- Research payments reported, 2025
- $106,307
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 35
About the trial
- Sponsor
- CSL Behring
- Tested
- CSL222 (AAV5-hFIXco-Padua) (genetic)
- Dates
- Started 2024-01-30; completion 2032-04-02
- Results posted
- Not yet
The purpose of this study is to assess the risk of bleeding due to failure of expected pharmacological action of CSL222 in adults with severe or moderately severe hemophilia B with detectable pretreatment AAV5 Nabs.
From ClinicalTrials.gov, last updated 2026-08-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $106,307 in research payments for this study in 2025 (17 payments).
Products named: Hemgenix
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Annette Von Drygalski, MD Hematology & Oncology · San Diego, CA
- Steven W. Pipe, MD Pediatric Hematology & Oncology · Ann Arbor, MI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Regents of the University of California San Diego $76,763
- University of Michigan Health System, MI $29,544
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.